“The outlook revision to negative reflects sharply weaker fiscal 2016 year-to-date performance through the nine-month unaudited period ended Sept. 30, 2016, combined with a meaningful decline in unrestricted reserves,” said S&P analyst Martin Arrick.
S&P also affirmed the “BBB” rating on DHHA’s series 2007A, 2007B, 2009A, 2010, 2014A and 2014B bonds. The rating affirmation reflects S&P’s view of DHHA’s strong enterprise profile and adequate financial profile.
More articles on healthcare finance:
MACPAC calls for extending CHIP federal funding through FY 2022
5 most-read finance stories: Week of Dec. 12-16
CMS adds advanced APM opportunities under MACRA
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
